Top news of the week: 23.11.2022.
Merck Acquires Imago and its LSD1 Inhibitors in $1.3B Deal (Updated)
With a $1.36 billion buyout, Merck bolstered its oncology program with the acquisition of Biotech Bay-based Imago Biosciences, a company focused on chronic bone marrow cancers.
FDA Greenlights Provention’s TZIELD as First Drug to Delay Advanced T1D
The FDA has approved Provention’s BLA for intravenous antibody TZIELD to delay stage 3 type 1 diabetes, making it the first disease-modifying drug indicated to slow disease ...
Legend Biotech small cell lung cancer drug gets FDA ok for clinical development
Legend Biotech has been cleared by the FDA to proceed with the clinical development of LB2102, a CAR-T therapy for the treatment of SCLC.
Beyond Biotech podcast 23: World Antimicrobial Awareness Week, PsychoGenics
This week, we mark World Antimicrobial Awareness Week with AiCuris, Destiny Pharma and QureTech Bio. We also talk to PsychoGenics and JLL.
Biggest drug companies halted Twitter ad buys after Lilly insulin spoof
Almost all of the drug industry's biggest advertisers cut their spending on Twitter to zero or near-zero over the last two weeks amid worries about impersonation of their brands by ...
Pfizer CEO says Covid vaccine will remain ‘free for all Americans,’ overlooking indirect costs
Pfizer's CEO says the company's Covid vaccines will remain "free for all Americans" — an assertion that overlooked indirect costs that will be passed on to consumers.
Accelerating Development of Revolutionary Biological Dyes
Rapid 2D barcode rack readers and automated tube picking equipment from Ziath are helping Colorifix (Norwich, UK) to accelerate development of revolutionary biological dyes to help the ...
Life sciences SPACs dwindle amid new SEC rules and excise tax
As IPOs have slowed significantly in 2022, so have the debuts of special purpose acquisition companies (SPACs) targeting the life sciences industry, primarily due to two looming threats. ...